Misplaced Pages

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

The Sanofi–GSK COVID-19 vaccine, sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK.

The Sanofi–GSK COVID‑19 vaccine was approved for medical use in the European Union in November 2022.

Medical uses

The Sanofi–GSK COVID‑19 vaccine is used as a booster for active immunisation against SARS‑CoV‑2 virus in order to prevent COVID‑19.

Pharmacology

The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine.

History

The Sanofi–GSK COVID‑19 vaccine is under development by the French pharmaceutical company Sanofi and the British-American pharmaceutical company GlaxoSmithKline. Advanced clinical trials of the vaccine were delayed in December 2020 after it failed to produce a strong immune response in people over the age of 50, most likely due to an insufficient antigen concentration in the vaccine, delaying the launch of the vaccine to late 2021.

Clinical trials

In September 2020, Sanofi-GSK started for phase I trials with 440 participants in the United States.

In February 2021, Sanofi-GSK started for phase II trials with 722 participants in the United States.

On 27 May 2021, the vaccine began a Phase III trial involving 35,000 participants, which increased to 37,430 participants with trials in Colombia, Dominican Republic, Ghana, Honduras, India, Japan, Kenya, Mexico, Nigeria, Pakistan, Sri Lanka, Uganda, and the United States.

In September 2021, Sanofi-GSK started a booster trial in the United Kingdom. In this study, they will enroll up to 3,145 volunteers who have previously completed a COVID-19 a full vaccine course between 4 and 10 months previously. The purpose of this study is to determine if the investigational COVID-19 vaccines are safe and can stimulate and broaden the immune response against the different COVID-19 variants that cause COVID-19 when given as a single booster injection in participants who have previously been vaccinated with a full course of an authorized COVID-19 vaccine.

Non-clinical studies

During its development, the vaccine was tested in several non-clinical models including mice, hamsters, rabbits and non-human primates.

Society and culture

Legal status

In July 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started a rolling review of Vidprevtyn, a COVID-19 vaccine developed by Sanofi Pasteur. The CHMP's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults, which suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease. Vidprevtyn Beta was approved for medical use in the European Union in November 2022.

Economics

In July 2020, the UK government signed up for 60 million doses of a COVID-19 vaccine developed by GSK and Sanofi. It uses a recombinant protein-based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021. The company also agreed to a $2.1 billion deal with the United States to produce 100 million doses of the vaccine.

Marketing

In March 2024, at the request of Sanofi Pasteur, the European Commission withdrew the marketing authorization for VidPrevtyn. Sanofi Pasteur said the decision for the discontinuation was due to commercial reasons.

See also

• Corbevax

References

1. ^ "VidPrevtyn Beta". European Medicines Agency (EMA). 4 November 2022. Retrieved 12 November 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
2. ^ "EMA recommends approval of VidPrevtyn Beta as a COVID 19 booster vaccine". European Medicines Agency (EMA) (Press release). 10 November 2022. Retrieved 12 November 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
3. "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
4. "Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older". pactr.samrc.ac.za. Pan African Clinical Trials Registry. Retrieved 24 March 2021.
5. "Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)". ClinicalTrials.gov. Retrieved 28 May 2021.
6. "Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission". GSK (Press release). 10 November 2022. Retrieved 12 November 2022.
7. "Press Release: Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission". Sanofi (Press release). 10 November 2022. Retrieved 12 November 2022.
8. "Sanofi, GSK announce positive results for Covid-19 vaccine candidate". STAT. 17 May 2021. Retrieved 18 May 2021.
9. "The Adjuvanted Recombinant Protein-based Vaccine Candidate". Sanofi. Archived from the original on 18 May 2021. Retrieved 18 May 2021.
10. "Coronavirus vaccine trial begun by drug firms GSK and Sanofi". BBC News Online. 3 September 2020. Retrieved 20 April 2021.
11. Taylor NP (11 December 2020). "Weak clinical data force Sanofi, GSK to delay COVID-19 vaccine". Fierce Biotech. Retrieved 25 January 2021.
12. "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older". ClinicalTrials.gov. 3 September 2020. NCT04537208.
13. "Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)". ClinicalTrials.gov. 21 February 2021. NCT04762680.
14. Armitage J (27 May 2021). "GlaxoSmithKline shareholders "relieved" as Elliott rules out aggressive demands". London Evening Standard.
15. "Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate". Sanofi (Press release). 27 May 2021. Retrieved 22 July 2021.
16. "Phase 3 Clinical Trial for COVID-19 Recombinant Protein Vaccine Candidate". Sanofi. Archived from the original on 23 July 2021. Retrieved 22 July 2021.
17. "Tarjeta del participante del estudio VAT00008: ejemplo central para adaptación a nivel de país" [VAT00008 Study Participant Card: Central Example for Country-Level Adaptation] (PDF). incmnsz.mx. Salvador Zubirán National Institute of Health Sciences and Nutrition. 15 April 2021.
18. "Safety and efficacy of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older". ctri.nic.in. Clinical Trials Registry India. CTRI/2021/06/034442. Retrieved 3 August 2021.
19. "Covid-19 Booster Vaccine Clinical Study". Sanofi. 22 October 2021. Archived from the original on 30 October 2021. Retrieved 22 October 2021.
20. Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Moore IN, et al. (August 2021). "Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates". Science Translational Medicine. 13 (607). doi:10.1126/scitranslmed.abi4547. PMC 9266840. PMID 34315825.
21. Pavot V, Berry C, Kishko M, Anosova NG, Huang D, Tibbitts T, et al. (March 2022). "Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates". Nature Communications. 13 (1): 1699. Bibcode:2022NatCo..13.1699P. doi:10.1038/s41467-022-29219-2. PMC 8971430. PMID 35361754.
22. Pavot V, Berry C, Kishko M, Anosova NG, Li L, Tibbitts T, et al. (March 2023). "Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates". Nature Communications. 14 (1): 1309. Bibcode:2023NatCo..14.1309P. doi:10.1038/s41467-023-36908-z. PMC 9998256. PMID 36894558.
23. Berry C, Pavot V, Anosova NG, Kishko M, Li L, Tibbitts T, et al. (May 2023). "Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters". Communications Medicine. 3 (1): 75. doi:10.1038/s43856-023-00302-z. PMC 10212738. PMID 37237062.
24. ^ "EMA starts rolling review of COVID-19 vaccine Vidprevtyn". European Medicines Agency (EMA) (Press release). 20 July 2021. Retrieved 22 July 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
25. "Vidprevtyn Beta Product information". Union Register of medicinal products. Retrieved 3 March 2023.
26. "Coronavirus vaccine: UK signs deal with GSK and Sanofi". BBC News. 29 July 2020.
27. Lovelace Jr B (31 July 2020). "U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine". CNBC.
28. "VidPrevtyn Beta" (PDF). European Medicines Agency.

External links

• Study of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older Protocol Archived 23 July 2021 at the Wayback Machine

• Medicine
• Viruses
• COVID-19

• Drugs developed by GSK plc
• American COVID-19 vaccines
• Products introduced in 2020
• Sanofi
• Protein subunit vaccines
• French COVID-19 vaccines
• British COVID-19 vaccines